ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2492 • ACR Convergence 2023

    The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life

    Rula Hajj-Ali1, Chao Zhang2, Renee Borchin3, Jenn Gordon4, David Cuthbertson3, Carol McAlear5, Christine Yeung5, David Badenoch6, Cristina Burroughs3 and Peter Merkel5, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH, 3University of South Florida, Tampa, FL, 4Vasculitis Patient Powered Research Network (VPPRN), Philadelphia, PA, 5University of Pennsylvania, Philadelphia, PA, 6Vasculitis Patient Powered Research Network (VPPRN), Los Angeles, CA

    Background/Purpose: Neurologic involvement (NI) is a common manifestation in patients with ANCA-associated vasculitis (AAV) and can lead to chronic pain and disability. This project assessed…
  • Abstract Number: 2502 • ACR Convergence 2023

    Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus

    Patti Katz1, Maria Dall'Era2, Jinoos Yazdany3 and Kaleb Michaud4, 1University of California San Francisco, San Rafael, CA, 2University of California San Francisco, San Francisco, CA, 3University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 4University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Research in the general population has linked sleep disorders to poor outcomes such as lower pain thresholds, fatigue, cognitive impairment, depression, and cardiovascular disease…
  • Abstract Number: 2510 • ACR Convergence 2023

    Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1

    Tineke van Wesemael1, Jessica Borgers2, Kyra Gelderman3, Els Verdegaal4, C.M. Korse5, M.J.P. Welters6, Ellen Kapiteijn7, W.J. van Houdt2, Sjoerd van der Burg6, René Toes1, J.V. Thienen2, John Haanen2 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands, 3Sanquin Diagnostic Services, Amsterdam, Netherlands, 4Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Amsterdam, Netherlands, 5Department of Laboratory Medicine, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, Netherlands, 6Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands, 7Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: PD-1 immune checkpoint inhibitors are able to re-activate restrained anti-tumor T-cell responses in melanoma patients. However, PD-1 inhibition may also activate auto-reactive T-cells leading…
  • Abstract Number: 2504 • ACR Convergence 2023

    The Effect of Inflammatory Conditions on the Regulation of Canonical and Non-canonical NF-kB Pathways via Bcl11b

    Sara Parsa1, Saeid Rahmani2, Nadine Davelaar1, Adriana M.C.mus1 and Erik Lubberts1, 1Erasmus Medical Center, Rotterdam, Netherlands, 2Institute for Research in Fundamental Sciences, Tehran, Iran

    Background/Purpose: Bcl11b, a zinc finger bi-functional transcription factor, is highly expressed in various tissues during development and differentiation, including stromal cells. It has been shown…
  • Abstract Number: 2268 • ACR Convergence 2023

    Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study

    Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan

    Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…
  • Abstract Number: 2509 • ACR Convergence 2023

    Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias

    Kaitlin McCarter1, Senada Arabelovic1, Taylor Wolfgang1, Xiaosong Wang1, Kazuki Yoshida1, Grace Qian1, Emily Kowalski1, Kathleen Vanni1, Nicole LeBoeuf1, Elizabeth Buchbinder2, Lydia Gedmintas1, Lindsey MacFarlane1, Deepak Rao1, Nancy Shadick3, Ellen Gravallese4 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Boston, MA, 2Dana-Farber Cancer Institute, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Immune checkpoint inhibitors (ICI) stimulate the immune system to treat cancer but may cause flares of pre-existing immune-mediated inflammatory diseases. Risk factors for ICI-induced…
  • Abstract Number: 2505 • ACR Convergence 2023

    Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders

    Kate Byth1, Rodney Morgan2, Pierre Michelys3, Kellie Demock2, Geetha Kannan2, Qing Chen1, Brian Sanchez2, Xiaokang Lu2, Alissa Telling2, Chuck Lesch2, Carmen Yu2, Sarah Bradley2, Brian Andresen1, Sherif Hassanien2, Clarke Taylor2, Zhilin Hou2, Ken Borrelli1, Anna Gardberg1, Erika Munschy1, Adam Schwaid1, Anthony Opipari2, Shifeng Pan3 and Luigi Franchi2, 1Odyssey Therapeutics, Boston, MA, 2Odyssey Therapeutics, Ann Arbor, MI, 3Odyssey Therapeutics, San Diego, CA

    Background/Purpose: Interleukin-1 receptor-associated kinase 4 (IRAK4), is a key node that mediates inflammatory signaling in response to activation of toll-like receptor (TLR) and IL-1 receptor…
  • Abstract Number: 2498 • ACR Convergence 2023

    Does Physical Activity Modify the Relationship Between Pain and Corticosteroid Injection Utilization in Adults with or at High Risk for Knee Osteoarthritis?

    Sydney Liles1, Daniel White2, Thomas Bye2 and Jason Jakiela2, 1University of Delaware, Elkton, MD, 2University of Delaware, Newark, DE

    Background/Purpose: Knee osteoarthritis (OA) is a leading global cause of pain and disability, with no current cure. Knee pain is the most common symptom and…
  • Abstract Number: 2503 • ACR Convergence 2023

    Cytokines Regulate the Fibrotic Response of Growth Factors in Joint Fibroblast-like Synoviocytes

    Sofie Falkenløve Madsen1, Mikkel Rathsach Andersen2, Alexander Scheller Madrid2, Signe Holm Nielsen3, Morten Karsdal3, Christian Thudium3 and Anne-Christine Bay-Jensen3, 1University of Copenhagen, Herlev, Denmark, 2Herlev-Gentofte Hospital, Gentofte, Denmark, 3Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) and osteoarthritis (OA) are characterized by inflammation, joint swelling, stiffness, and pain. A fibroid phenotype has been identified in RA, where…
  • Abstract Number: 2481 • ACR Convergence 2023

    Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy

    Matthew Wright1, Mette Smed2, Lee Nelson3, Jørn Olsen4, Merete Hetland5, Nicholas Jewell6, Vibeke Zoffmann2 and Damini Jawaheer1, 1Northwestern University, Chicago, IL, 2Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, 3Fred Hutchinson Cancer Center, Seattle, WA, 4Aarhus University Hospital, Aarhus, Denmark, 5Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 6London School of Hygiene and Tropical Medicine, London, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) can improve naturally during pregnancy in a substantial proportion of women (50-75%), while it may worsen or remain unchanged in others.…
  • Abstract Number: 2406 • ACR Convergence 2023

    Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study

    Mohanad Elfishawi1, Mahmut Kaymakci1, Sara Achenbach2, Cynthia Crowson1, Tanaz Kermani3, Cornelia M. Weyand4, Matthew Koster1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, Rochester, MN, 3University of California Los Angeles, Los Angeles, CA, 4Mayo Clinic School of Medicine and Stanford University, Rochester, MN

    Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
  • Abstract Number: 2278 • ACR Convergence 2023

    Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry

    Cristiana Sieiro Santos1, Paula Pérez García2, Jose Ordas Martínez2, Clara Moriano2, Carolina Álvarez Castro2 and Elvira Díez Álvarez2, 1Complejo Asistencial Universitario de León, León, Spain, 2CAULE, León, Spain

    Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
  • Abstract Number: 2489 • ACR Convergence 2023

    Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Achievement and Sustained Response with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE

    Cristina Arriens1, Ronald van Vollenhoven2, Alice B. Gottlieb3, Coburn Hobar4, Samantha Pomponi4, Ravi Koti5, Thomas Wegman6 and Victoria P. Werth7, 1Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4Bristol Myers Squibb, Princeton, NJ, 5Syneos Health, Morrisville, NC, 6Bristol Myers Squibb, Beaver Falls, PA, 7University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis. A…
  • Abstract Number: 2496 • ACR Convergence 2023

    HXB-319, a New Generation Mesenchymal Stromal Cell (MSC) Therapy, Alleviates Neutrophilic Inflammation, and End-organ Damage in Pulmonary Renal Syndromes by Inducing FoxP3+ Tregs, and by Promoting TNFα-stimulated gene-6 (TSG-6) over Expression

    Hulya Bukulmez1, Adrienne Dennis1, Jane Reese-Koc2, Scott Sieg2 and Steven Emancipator2, 1MetroHealth Medical Center, Department of Pediatrics, Cleveland, OH, 2Case Western Reserve University, Cleveland, OH

    Background/Purpose: Mesenchymal stromal cells (MSCs) have been shown to be safe therapies in more than 100 human clinical trials. However, MSCs clinical efficacy is variable,…
  • Abstract Number: 2517 • ACR Convergence 2023

    The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease

    Erdem Bektas1, Rabia Deniz2, Zeliha Emrence3, Sema Sırma Ekmekci3, Neslihan Abacı3, Shirkhan Amikishiyev4, Yasemin Yalçınkaya4, Bahar Artim Esen4, Murat Inanç5 and Ahmet Gul6, 1Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, 2University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, 3Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Istanbul University, Istanbul, Turkey, 6Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Background/Purpose: Behcet disease (BD) is a multisystemic inflammatory disease of unknown etiology. BD has been classified among the neutrophilic dermatosis, and neutrophil extracellular traps (NETs)…
  • « Previous Page
  • 1
  • …
  • 355
  • 356
  • 357
  • 358
  • 359
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology